Akebia Therapeutics
Get Full AccessDescription
- Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebias lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebias global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at www.akebia.com.
-
Headquarters:245 First Street Suite 1400, Cambridge, Massachusetts, United States
More -
Phone Number: +1 617-871-2098
-
Website: http://akebia.com/
-
Employees:394
-
Revenue:$250 - 500M
-
Legal Name:Akebia Therapeutics
-
Akebia Therapeutics's Social Media
-
Is this data correct?
-
| NAICS Code: 325412 |
Show More
Frequently Asked Questions regarding Akebia Therapeutics
-
Where are Akebia Therapeutics's Headquarters?
Akebia Therapeutics's Headquarters are in 245 First Street Suite 1400,Cambridge,Massachusetts,United States
-
What is Akebia Therapeutics's phone number?
Akebia Therapeutics's phone number is +1 617-871-2098
-
What is Akebia Therapeutics's official website?
Akebia Therapeutics's official website is http://akebia.com/
-
What is Akebia Therapeutics's Revenue?
Akebia Therapeutics's revenue is $250 - 500M
-
What is Akebia Therapeutics's NAICS code?
Akebia Therapeutics's NAICS code is 325412
-
How many employees are working in Akebia Therapeutics
Akebia Therapeutics has 394 employees
-
What is Akebia Therapeutics's Industry?
Akebia Therapeutics is in the industry of Biotechnology
-
Who is Akebia Therapeutics's CEO?
Akebia Therapeutics's CEO is John Butler

